Predictors of Perioperative Vasoactive Drug Requirement During Retroperitoneal Adrenalectomy for Pheochromocytoma: A Retrospective Exploratory Study

Abstract

The aim of the present study was to test a hypothesis that baseline systemic vascular resistance index (SVRI) assessed by method of transpulmonary thermodilution predicts perioperative requirement for vasoactive drugs. The primary outcomes were: (1) peak vasoactive-inotropic score (VIS) and (2) peak dose of hypotensive drugs at any stage of surgery. The main exposure variable was baseline SVRI. Hemodynamics were retrospectively assessed by transpulmonary thermodilution in 50 adults who had undergone posterior retroperitoneal surgery for pheochromocytoma. Univariate linear regression analysis showed predictive value of SVRI on VIS [regression coefficient, 95% CI; 0.024 (0.005, 0.4), p=0.015]. Other significant factors were the history of peak diastolic pressure, baseline MAP, baseline betablocker therapy, and history of coronary artery disease (CAD). After adjustment of SVRI for the history of CAD, its prognostic value became non-significant [0.018 (0.008, 0.03), p=0.063 and 29.6 (19, 40.2), p=0.007 for SVRI and history of CAD, respectively]. Requirements of vasodilators were predicted by baseline adrenergic activity [0.37 (0.005, 0.74), p=0.047]. In conclusion, baseline SVRI is associated with perioperative requirement of vasopressor drugs, but history of CAD is a stronger prognostic factor for vasopressor support. Perioperative requirement in vasodilators is associated with baseline adrenergic activity.

Key words

pheochromocytoma - transpulmonal thermodilution - vasoactive inotropic score - predictors vasopressor use

Publikationsverlauf

Eingereicht: 05. Mai 2021

Angenommen nach Revision: 15. September 2021

Artikel online veröffentlicht:
05. November 2021

• References

• 1 Bajwa S, Bajwa S. Implications and considerations during pheochromocytoma resection: A challenge to the anesthesiologist. Indian J Endocrinol Metab 2011; 15: 337
• 2 Livingstone M, Duttchen K, Thompson J. et al Hemodynamic stability during pheochromocytoma resection: Lessons learned over the last two decades. Ann Surg Oncol 2015; 22: 4175-4180
• 3 Naranjo J, Dodd S, Martin YN. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2017; 31: 1427-1439
• 4 Groeben H, Walz MK, Nottebaum BJ. et al International multicentre review of perioperative management and outcome for catecholamine-producing tumours. Br J Surg 2020; 107: e170-e178
• 5 Grocott HP. Safety assessments in the avoidance of preoperative α-receptor blockade in phaeochromocytoma surgery: the pitfalls of a zero numerator. Br J Anaesth 2017; 119: 545-546
• 6 Schimmack S, Kaiser J, Probst P. et al Meta-analysis of α-blockade versus no blockade before adrenalectomy for phaeochromocytoma. Br J Surg 2020; 107: e102-e108
• 7 Weingarten TN, Welch TL, Moore TL. et al Preoperative levels of catecholamines and metanephrines and intraoperative hemodynamics of patients undergoing pheochromocytoma and paraganglioma resection. Urology 2017; 100: 131-138
• 8 Gaujoux S, Bonnet S, Lentschener C. et al Preoperative risk factors of hemodynamic instability during laparoscopic adrenalectomy for pheochromocytoma. Surg Endosc 2016; 30: 2984-2993
• 9 Wolf KI, Santos JRU, Pacak K. Why take the risk? We only live once: the dangers associated with neglecting a pre-operative alpha adrenoceptor blockade in pheochromocytoma patients. Endocr Pract 2019; 25: 106-108
• 10 Gaies MG, Gurney JG, Yen AH. et al Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. 2010; 11: 234-238
• 11 Koponen T, Karttunen J, Musialowicz T. et al Vasoactive-inotropic score and the prediction of morbidity and mortality after cardiac surgery. Br J Anaesth 2019; 122: 428-436
• 12 Walz MK, Peitgen K, Walz MV. et al Posterior retroperitoneoscopic adrenalectomy: Lessons learned within five years. World J Surg 2001; 728-734
• 13 Grocott HP. Perioperative considerations in the management of pheochromocytoma: The details behind the changing dogma. J Cardiothorac Vasc Anesth 2018; 32: e11-e12
• 14 Rao N, Ramachandran R, Tandon N. et al Surgical and hemodynamic outcomes in pheochromocytoma surgery: a prospective cohort study. Urology 2016; 98: 103-106
• 15 Hemodynamic monitoring lessons from the ICU. Michael R. Pinsky, Jean-Louis Teboul J-L, Vincent J-L. Eds Berlin: Springer; 2019
• 16 Perioperative hemodynamic monitoring and goal directed therapy: From theory to practice Cannesson M, Pearse R. Eds Cambridge: Cambridge University Press; 2014
• 17 Groeben H, Nottebaum BJ, Alesina PF. et al Perioperative α-receptor blockade in phaeochromocytoma surgery: An observational case series. Br J Anaesth 2017; 118: 182-189
• 18 Tufton N, Gunganah K, Hussain S. et al Alpha blockade – not to be underdone. Clin Endocrinol (Oxf) 2017; 86: 306-308
• 19 Challis BG, Casey RT, Simpson HL. et al Is there an optimal preoperative management strategy for phaeochromocytoma/paraganglioma?. Clin Endocrinol (Oxf) 2017; 86: 163-167